A novel photostable near-infrared fluorescent selective estrogen receptor modulator (SERM) for live-cell 3D imaging of breast cancer

Estrogen receptor (ER) is a major transcriptional regulator that plays an important role in the treatment of breast cancer. Herein, we rationally designed and synthesized a novel small-molecule near-infrared (NIR) fluorescent probe, 2-(4-(2-(2,5-bis(2-fluoro-4-hydroxyphenyl)thiophen-3-yl)vinyl)− 3-c...

Full description

Saved in:
Bibliographic Details
Published in:Sensors and actuators. B, Chemical Chemical, 2024-05, Vol.407, p.135454, Article 135454
Main Authors: Yang, Chunmei, He, Pei, Meng, Qiuyu, Dong, Chune, Zhou, Hai-Bing, Yang, Lu
Format: Article
Language:English
Subjects:
Estrogen receptor
Live-cell 3D imaging
NIR fluorescent probes
Photostable probes
SERM
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Estrogen receptor (ER) is a major transcriptional regulator that plays an important role in the treatment of breast cancer. Herein, we rationally designed and synthesized a novel small-molecule near-infrared (NIR) fluorescent probe, 2-(4-(2-(2,5-bis(2-fluoro-4-hydroxyphenyl)thiophen-3-yl)vinyl)− 3-cyano-5,5-dimethylfuran-2(5 H)ylidene)malononitrile (TCFT), which could enable prolonged live-cell imaging by three-dimensional (3D) confocal microscopy. Moreover, this bifunctional probe also exhibited photostability, selective estrogen receptor modulator activity, and potent antiproliferative activity for targeted breast cancer therapy, which would be a prominent NIR fluorescent probe for breast cancer study. [Display omitted] •A novel photostable NIR fluorescent probe TCFT was developed for estrogen receptor.•TCFT was successfully applied in prolong live-cell imaging of estrogen receptor by 3D confocal microscopy.•TCFT exhibited selective estrogen receptor modulator activity and potent antiproliferative activity for breast cancer therapy.•TCFT possessed the potential as a theranostic probe for estrogen receptor (+) breast cancer study.
ISSN:0925-4005
1873-3077
DOI:10.1016/j.snb.2024.135454